Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim
Author:
Funder
Arnold Ventures LLC
Publisher
Elsevier BV
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference5 articles.
1. Uptake of the biologic filgrastim and its biosimilar product among the Medicare population;Kozlowski;JAMA,2018
2. Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US;Mues;Clin Epidemiol,2017
3. The financial impact of the sequester cut to Medicare Part B drug reimbursement in community oncology;Gordan;Am J Manag Care,2018
4. Friction in the path to use of biosimilar drugs;Frank;N Engl J Med,2018
5. Biologics: the new antitrust frontier;Carrier;Univ Ill Law Rev,2018
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A primer on brand-name prescription drug reimbursement in the United States;Journal of Managed Care & Specialty Pharmacy;2024-01-01
2. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019;Journal of Managed Care & Specialty Pharmacy;2024-01-01
3. Biosimilars engage in low levels of direct-to-physician marketing relative to reference biologics;Health Affairs Scholar;2023-12
4. Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021;JCO Oncology Practice;2023-07
5. The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program;Health Affairs;2023-05-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3